TLSI · TriSalus Life Sciences, Inc.
$5.27
-0.36 (-6.39%)
At close · Aug 14
Going-concern doubt
— cleared Aug 6, 2026
The latest filing no longer states the doubt (first flagged May 12, 2026).
View the 10-Q filed Aug 6, 2026Market Cap
$324.50M
Shares
61.57M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$45.15M
+53.4%
FY2025
Net Income
-$39.23M
-30.6%
FY2025
Gross Margin
84.57%
-1.5pp
FY2025
Operating Margin
-59.68%
+63.2pp
FY2025
Diluted EPS
-$1.84
-40.5%
FY2025
Operating Cash Flow
-$18.01M
+55.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $54M – $57M | $45.08M | $45.15M | $29.43M | $18.51M | $12.4M | — | — | |
| — | $6.41M | $6.97M | $4.1M | $2.61M | $2.26M | — | — | |
| — | $38.67M | $38.19M | $25.33M | $15.91M | $10.14M | — | — | |
| — | — | 84.57% | 86.06% | 85.93% | 81.79% | — | — | |
| — | $14.63M | $14.97M | $17.69M | $29.84M | $21.36M | — | — | |
| — | $33.64M | $28.71M | $25.84M | $17.03M | $12.74M | — | — | |
| — | $20.91M | $21.46M | $17.97M | $23.51M | $12.48M | $3.04M | $108.49K | |
| — | — | — | — | $18K | $122K | — | — | |
| — | — | $626K | $744K | $684K | $398K | — | — | |
| — | -$30.51M | -$26.95M | -$36.17M | -$54.48M | -$36.44M | -$3.04M | -$108.49K | |
| — | — | -59.68% | -122.88% | -294.28% | -293.91% | — | — | |
| — | — | -$26.32M | -$35.42M | -$53.79M | -$36.04M | — | — | |
| — | $5.84M | $5.54M | $3.09M | $16K | $1000 | — | — | |
| — | $968K | $555K | $404K | $431K | $180K | $64K | $3298 | |
| — | -$151K | -$456K | -$312K | -$378K | $8.86M | $7.81M | -$602.9K | |
| — | -$28.2M | -$39.22M | -$30.04M | -$59.35M | -$47.18M | $4.77M | — | |
| — | $13K | $7000 | $6000 | $9000 | $9000 | $0 | — | |
| — | -$28.21M | -$39.23M | -$30.05M | -$59.36M | -$47.19M | $4.77M | -$711.39K | |
| — | — | -86.88% | -102.09% | -320.69% | -380.6% | — | — | |
| — | -$57.25M | -$69.69M | -$33.23M | -$63.6M | -$50.02M | — | — | |
| USD/shares | — | — | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — | — |
| USD/shares | — | — | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — | — |
| shares | — | — | 37.9M | 25.33M | 9.4M | 309.61K | — | — |
| shares | — | — | 37.9M | 25.33M | 9.4M | 309.61K | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.40×
EV/EBIT
—
Peer median 22.11×
P/E (TTM)
—
Peer median 31.70×
Peer medians compare against the 83 similar-size Medical Devices companies (of 148 listed).
Key facts
CIK
1826667
CUSIP
89680M101
13F (30d)
78 filings
78 filers
Visit website
Investor relations